0) && (parseInt(navigator.appVersion) >= 4)) { Post-acquisition, Sirtris will become part of Glaxo's drug discovery organization, while continuing to operate from laboratories in Cambridge, Mass., as an autonomous drug discovery unit. And Sirtris/GSK faces long years of rigorous research before this nook of the anti-aging field yields a marketed drug. GlaxoSmithKline today announced that it is going to acquire Sirtris (NASDAQ:SIRT) for $720 million through a cash tender offer of $22.50 per share. via: Sirtris The planned purchase of the biopharma comes at a $10-a-share premium over Tuesday's closing price. SIRTRIS PHARMA INC. Weekly Stock Prices Chart. The $22.50 per Sirtris share that GSK paid as part of the deal represented a nearly 85 percent premium to Sirtris’ stock price at the time the deal was announced. Their stock opened with $10.00 in its May 23, 2007 IPO. READ MORE Prior to co-founding our company, Dr. Milne worked as head of discovery biology at Sirtris Pharmaceuticals, a biotechnology company, from 2004 to 2008, when it was acquired by GlaxoSmithKline. GlaxoSmithKline (GSK) to Acquire Sirtris Pharmaceuticals, a World Leader in "Sirtuin" Research and Development for $720M 4/23/2008 LONDON, PHILADELPHIA AND … Action Alerts PLUS is a registered trademark of TheStreet, Inc. Sirtris Pharmaceuticals Inc. Another hot stock is Sirtris Pharmaceuticals. Sirtris is the most high-profile shop working on sirtuins and resveratrol-like pharmacology, which subject has received a massive amount of … When I pointed at Sirtris Pharmaceuticals in February I was considering to invest in that stock but had no money left. //-->. Developer of proprietary, orally administrable, small molecule biopharmaceutical drugs intended to cure type 2 diabetes, cancer, and other diseases. Sirtris is a biopharmaceutical company that's developing drugs to target a class of enzymes called sirtuins. Sirtris Pharmaceuticals has established a drug discovery capability to exploit sirtuin modulation for the treatment of human disease, an approach that has the potential to generate multiple clinically and commercially important products. GSK paid $22.50/share, when Sirtris's stock was trading at $12/share, down 45% from its highest price of the previous year. Markets Data Center: Biggest Price Gainers. . Developer of proprietary, orally administrable, small molecule biopharmaceutical drugs intended to cure type 2 diabetes, cancer, and other diseases. Sirtris is a biopharmaceutical company that's developing drugs to target a class of enzymes called sirtuins. Sirtris Pharmaceuticals has established a drug discovery capability to exploit sirtuin modulation for the treatment of human disease, an approach that has the potential to generate multiple clinically and commercially important products. GSK paid $22.50/share, when Sirtris's stock was trading at $12/share, down 45% from its highest price of the previous year. Markets Data Center: Biggest Price Gainers. 0) && (parseInt(navigator.appVersion) >= 4)) { Post-acquisition, Sirtris will become part of Glaxo's drug discovery organization, while continuing to operate from laboratories in Cambridge, Mass., as an autonomous drug discovery unit. And Sirtris/GSK faces long years of rigorous research before this nook of the anti-aging field yields a marketed drug. GlaxoSmithKline today announced that it is going to acquire Sirtris (NASDAQ:SIRT) for $720 million through a cash tender offer of $22.50 per share. via: Sirtris The planned purchase of the biopharma comes at a $10-a-share premium over Tuesday's closing price. SIRTRIS PHARMA INC. Weekly Stock Prices Chart. The $22.50 per Sirtris share that GSK paid as part of the deal represented a nearly 85 percent premium to Sirtris’ stock price at the time the deal was announced. Their stock opened with $10.00 in its May 23, 2007 IPO. READ MORE Prior to co-founding our company, Dr. Milne worked as head of discovery biology at Sirtris Pharmaceuticals, a biotechnology company, from 2004 to 2008, when it was acquired by GlaxoSmithKline. GlaxoSmithKline (GSK) to Acquire Sirtris Pharmaceuticals, a World Leader in "Sirtuin" Research and Development for $720M 4/23/2008 LONDON, PHILADELPHIA AND … Action Alerts PLUS is a registered trademark of TheStreet, Inc. Sirtris Pharmaceuticals Inc. Another hot stock is Sirtris Pharmaceuticals. Sirtris is the most high-profile shop working on sirtuins and resveratrol-like pharmacology, which subject has received a massive amount of … When I pointed at Sirtris Pharmaceuticals in February I was considering to invest in that stock but had no money left. //-->. Developer of proprietary, orally administrable, small molecule biopharmaceutical drugs intended to cure type 2 diabetes, cancer, and other diseases. Sirtris is a biopharmaceutical company that's developing drugs to target a class of enzymes called sirtuins. Sirtris Pharmaceuticals has established a drug discovery capability to exploit sirtuin modulation for the treatment of human disease, an approach that has the potential to generate multiple clinically and commercially important products. GSK paid $22.50/share, when Sirtris's stock was trading at $12/share, down 45% from its highest price of the previous year. Markets Data Center: Biggest Price Gainers.
(73) 3011 8400
contato@alanaqueiroz.com.br
CRM-Ba 25500
Instagram
RSS
dra-alana-queiroz-logo-v2dra-alana-queiroz-logo-v2

The stock market hasn't been kind to Sirtris, which was trading at $12, down 45% from its 52-week high. Sirtris Pharmaceuticals is registered under the ticker NASDAQ:SIRT . Latest Deal Amount. The company also has discovered new chemical entities that are significantly more potent activators of SIRT1 and should enter the clinic this year, according to some analysts. The startup’s activity is discovering and developing proprietary, orally available, small molecule drugs with the potential to treat metabolic diseases such as Type 2 Diabetes and such of aging by modulating sirtuins, a recently discovered class of enzymes. The news comes a day before Glaxo's quarterly earnings release. Sirtris Pharmaceuticals Presents Results of Studies of SIRT1 Activators at 6th Annual Metabolic Diseases Drug Discovery and Development World Summit, July 17, 2007 CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul 17, 2007 - Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat … [Updated 2:25 pm ET, 3/13/13] GlaxoSmithKline is closing down Cambridge, MA-based Sirtris Pharmaceuticals, almost five years after it paid $720 million to … Big pharma companies, pained by generic competition, have turned to licensing deals and acquisitions to bolster their pipelines. GlaxoSmithKline (GSK) - Get Report announced Tuesday after the market closed that it is buying Sirtris Pharmaceuticals (SIRT) for $720 million, or $22.50 a share. Sirtris Pharmaceuticals Files for $60 Million IPO Published: Mar 01, 2007 CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sirtris Pharmaceuticals Inc. today announced that it has filed a registration statement with the Securities and Exchange Commission relating to the proposed initial public offering of its common stock. Its SIRT-501, which is in early-stage development, is an enhanced formulation of resveratrol (the healthful agent found in red wine) that targets one of those enzymes, SIRT1. Sirtris Pharmaceuticals ' first drug is a treatment for diabetes. TradingCharts.com offers over 30 thousand free stock price charts and stock market quotes. Sirtris Pharmaceuticals (NASDAQ: SIRT) is a biopharmaceutical company focused on discovering and developing proprietary, orally available, small molecule drugs with the potential to treat diseases associated with aging, including metabolic diseases such as Type 2 Diabetes. Sirtris shares closed down 4% Tuesday prior to the news, at $12.23. Type 2 Diabetes (T2D) has reached epidemic proportions in the United States. Markets Data Center: Biggest Price Gainers. Sirtris Pharmaceuticals™ (NASDAQ: SIRT) is a biopharmaceutical company focused on discovering and developing proprietary, orally available, small molecule drugs with the potential to treat diseases associated with aging, including metabolic diseases such as Type 2 Diabetes. Sirtris Pharmaceuticals, Inc. SEC Form 4 Filed December 4, 2007: Statement of changes in beneficial ... Last Updated December 17, 2020 at 7:56 AM EST Back to Sirtris Pharmaceuticals, Inc. Description. Sirtris founder and CEO Christoph Westphal will remain head of the unit once the cash sale of about $22.50 per share closes later this year. $376M. } News Corp is a network of leading companies in the worlds of diversified media, news, education, and information services © 2021 TheStreet, Inc. All rights reserved. This stock price chart for SIRTRIS PHARMA INC., symbol SIRT, Nasdaq Stock Exchange is updated GBP11.33) per share followed by a second step merger in which any untendered Sirtris shares would be acquired at the same price per share. Sirtris Pharmaceuticals Inc. filed with regulators on Thursday to raise up to $60 million in an initial public offering of common stock. News Corp is a network of leading companies in the worlds of diversified media, news, education, and information services A high-level overview of Sirtris Pharmaceuticals (SIRT) stock. Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more. The proposed acquisition of Sirtris Pharmaceuticals (SIRT) is essentially aneffort to bolster GlaxoSmithKline's (NYSE:GSK)s pipeline in the Type 2 diabetes treatmentarea. Under the agreement, a subsidiary of GSK will commence a cash tender offer to purchase all of the outstanding shares of Sirtris, at USD22.50 (or approx. The acquisition has been approved by the boards of both companies, and is expected to close in the second quarter. Sirtris Pharmaceuticals (NASDAQ:SIRT) ... as seen by today's 15% drop in the stock price, the stock still looks a little overpriced for a company with one drug in … As part of a potential partnership with GlaxoSmithKline, Sirtris suggested the British pharmaceuticals giant buy a stake for $25 per share, nearly double Sirtris's stock price at the time. if ((navigator.appVersion.indexOf("MSIE") > 0) && (parseInt(navigator.appVersion) >= 4)) { Post-acquisition, Sirtris will become part of Glaxo's drug discovery organization, while continuing to operate from laboratories in Cambridge, Mass., as an autonomous drug discovery unit. And Sirtris/GSK faces long years of rigorous research before this nook of the anti-aging field yields a marketed drug. GlaxoSmithKline today announced that it is going to acquire Sirtris (NASDAQ:SIRT) for $720 million through a cash tender offer of $22.50 per share. via: Sirtris The planned purchase of the biopharma comes at a $10-a-share premium over Tuesday's closing price. SIRTRIS PHARMA INC. Weekly Stock Prices Chart. The $22.50 per Sirtris share that GSK paid as part of the deal represented a nearly 85 percent premium to Sirtris’ stock price at the time the deal was announced. Their stock opened with $10.00 in its May 23, 2007 IPO. READ MORE Prior to co-founding our company, Dr. Milne worked as head of discovery biology at Sirtris Pharmaceuticals, a biotechnology company, from 2004 to 2008, when it was acquired by GlaxoSmithKline. GlaxoSmithKline (GSK) to Acquire Sirtris Pharmaceuticals, a World Leader in "Sirtuin" Research and Development for $720M 4/23/2008 LONDON, PHILADELPHIA AND … Action Alerts PLUS is a registered trademark of TheStreet, Inc. Sirtris Pharmaceuticals Inc. Another hot stock is Sirtris Pharmaceuticals. Sirtris is the most high-profile shop working on sirtuins and resveratrol-like pharmacology, which subject has received a massive amount of … When I pointed at Sirtris Pharmaceuticals in February I was considering to invest in that stock but had no money left. //-->. Developer of proprietary, orally administrable, small molecule biopharmaceutical drugs intended to cure type 2 diabetes, cancer, and other diseases. Sirtris is a biopharmaceutical company that's developing drugs to target a class of enzymes called sirtuins. Sirtris Pharmaceuticals has established a drug discovery capability to exploit sirtuin modulation for the treatment of human disease, an approach that has the potential to generate multiple clinically and commercially important products. GSK paid $22.50/share, when Sirtris's stock was trading at $12/share, down 45% from its highest price of the previous year. Markets Data Center: Biggest Price Gainers.